Olfactory and gustatory disorders in COVID-19.
Allergo J Int
; 31(7): 243-250, 2022.
Article
in English
| MEDLINE | ID: covidwho-2266733
ABSTRACT
Loss of olfaction is one of the symptoms most commonly reported by patients with coronavirus disease 2019 (COVID-19). Although the spontaneous recovery rate is high, recent studies have shown that up to 7% of patients remain anosmic for more than 12 months after the onset of infection, leaving millions of people worldwide suffering from severe olfactory impairment. Olfactory training remains the first recommended treatment. With the continued lack of approved drug treatments, new therapeutic options are being explored. This article reviews the current state of science on COVID-19-related olfactory disorders, focusing on epidemiology, pathophysiology, cure rates, currently available treatment options, and research on new treatments.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Language:
English
Journal:
Allergo J Int
Year:
2022
Document Type:
Article
Affiliation country:
S40629-022-00216-7
Similar
MEDLINE
...
LILACS
LIS